ReviewFrontiers in immunology2025
Inflammatory factors collaboratively link
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Identification of potential hub biomarkers for gastric high-grade intraepithelial neoplasia early diagnosis: evidence from gene expression profiles and pathological characters.Translational cancer research · 2026Article
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- Molecular Insights intoCancers · 2026Review
- Preoperative Lactate Dehydrogenase-to-Albumin Ratio and Overall Survival in Gastric Cancer: Stage-Specific Prognostic Implications.Cancer management and research · 2026Article
- FOS Knockdown Alleviates Helicobacter pylori-Infected Gastritis by Suppressing Mast Cell Activation and Treg Polarization.Mediators of inflammation · 2026Article
- Immune modulation in gastric cancer: from macrophage polarization to immunotherapy.Frontiers in immunology · 2026Review
- Dietary carotenoids and vitamin A are associated with lower gastric cancer risk and favorable inflammatory and oxidative stress biomarkers: an incident case- control study.Frontiers in nutrition · 2026Article
- Editorial: The role of bioactive compounds and nutrients in intestinal mucosal immunity, liver and vascular inflammation.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term inflammatory reaction may promote gastric cancer initiation and development through multiple mechanisms. Recent studies have demonstrated that inflammatory mediators play a crucial role in the transition from gastritis to gastric cancer. Pro-inflammatory cytokines, chemokines, and other signaling molecules interact and synergistically regulate gastric epithelial cell proliferation, apoptosis, migration, and invasiveness, thereby promoting tumorigenesis. Specifically, interleukins activate immune cells, induce the secretion of inflammatory mediators, and maintain local immune responses; however, in the context of cancer, they exhibit a dual role by both enhancing anti-tumor immunity and driving tumor progression. Tumor necrosis factor amplifies immune responses by stimulating the production of pro-inflammatory cytokines, yet excessive or chronic Tumor necrosis factor activity is a hallmark of autoimmune diseases. Interferons initiate antiviral responses, modulate immune cell functions, and influence the inflammatory cascade. Chemokines primarily mediate the recruitment of immune cells to sites of infection, inflammation, or injury, but also play key roles in immune evasion and tumor immune regulation. This review summarizes the cooperative roles of these inflammatory mediators in the progression from gastritis to gastric cancer and discusses their potential as therapeutic targets. A better understanding of these mechanisms may facilitate the development of novel strategies for the prevention and treatment of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.